Mantle Cell Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

LCM MCID: MNT001 MIFTS: 67	Mantle Cell Lymphoma (LCM) Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

IMPROVED

Name: Mantle Cell Lymphoma ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵ ¹⁴ ³⁶ ¹⁶ ³¹ ³³

Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse ⁷¹

Malignant Lymphoma - Lymphocytic, Intermediate Differentiation ⁷¹

Malignant Undifferentiated Cell, Non-Burkitt Lymphoma ³³

Malignant Small Cell, Noncleaved, Diffuse Lymphoma ³³

Diffuse Non-Hodgkin Small Cleaved Cell Lymphoma ³³

Diffuse Small Cleaved Cell Malignant Lymphoma ³³

Small Cleaved Cell Non-Hodgkin Lymphoma ³³

Small Cleaved Cell Malignant Lymphoma ³³

Diffuse Small Cleaved-Cell Lymphoma ³³

Malignant Lymphomatous Polyposis ³³

Small Cell Mantle Cell Lymphoma ³³

Lymphoma, Mantle Cell ¹⁹

Lymphoma, Mantle-Cell ⁴³

Cleaved Cell Lymphoma ³³

Mantle Zone Lymphoma ⁵⁸

Lymphoma Mantle-Cell ⁵³

Mcl ⁵⁸

Lcm ⁵⁸

Characteristics:

Inheritance:

Multigenic/multifactorial ⁵⁸

Prevelance:

1-9/1000000 (United States) 1-9/100000 (Europe, France) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Age Of Death:

adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Non-follicular lymphoma

Mantle cell lymphoma

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature B-cell neoplasms

Other specified mature B-cell neoplasms or lymphoma

Mantle cell lymphoma

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:0050746

MeSH ⁴³ D020522

ICD10 ³¹ C83.1

MESH via Orphanet ⁴⁴ D020522

ICD10 via Orphanet ³² C83.1

UMLS via Orphanet ⁷² C0555202

Orphanet ⁵⁸ ORPHA52416

SNOMED-CT via HPO ⁶⁹ 109979007 119292006 127035006 more

EFO ¹⁶ EFO_1001469

ICD11 ³³ 1804127841

UMLS ⁷¹ C0334634 C0555202

Sources

Summaries for Mantle Cell Lymphoma

GARD: ¹⁹ Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed.

MalaCards based summary: Mantle Cell Lymphoma, also known as malignant lymphoma, lymphocytic, intermediate differentiation, diffuse, is related to lymphoma and burkitt lymphoma. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are Cellular responses to stimuli and Prolactin Signaling. The drugs Cyclophosphamide and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, lymph node and t cells, and related phenotypes are lymphadenopathy and b-cell lymphoma

Orphanet: ⁵⁸ Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma (see this term) affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''.

Disease Ontology: ¹¹ A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia: ⁷⁵ Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL), comprising about 6% of NHL cases.... more...

Sources

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 599)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoma	33.3	MDM2 IRF4 GAS5 EZH2 CDKN2C CDKN2A
2	burkitt lymphoma	33.1	IRF4 CDKN2A CD44 CCND2 BMI1 BCL6
3	lymphoma, hodgkin, classic	32.8	MDM2 IRF4 BCL6 BCL2 ATM
4	b-cell lymphoma	32.7	MDM2 MALAT1 IRF4 IGH GAS5 EZH2
5	lymphoma, non-hodgkin, familial	32.7	MDM2 IRF4 IGH EZH2 CDKN2C CD44
6	leukemia, chronic lymphocytic	32.6	MTOR MIR16-1 MDM2 IRF4 IGH EZH2
7	follicular lymphoma	32.3	MTOR IRF4 IGH EZH2 CDKN2A CCND1
8	b-cell non-hodgkin lymphoma	32.2	BCL6 ATM
9	diffuse large b-cell lymphoma	32.2	MDM2 IRF4 EZH2 BCL6 BCL2
10	marginal zone b-cell lymphoma	32.1	IRF4 CCND1 BCL6 BCL2
11	leukemia	32.1	GAS5 CDKN2A CCND1 BMI1 BCL2 ATM
12	lymphoma, mucosa-associated lymphoid type	31.9	IRF4 IGH CCND1 BCL6 BCL2
13	hematologic cancer	31.9	MTOR MIR16-1 IRF4 BMI1 BCL2 ATM
14	chronic lymphocytic leukemia/small lymphocytic lymphoma	31.8	CCND1 BCL6 BCL2
15	myeloma, multiple	31.8	MTOR MALAT1 IRF4 GAS5 CDKN2C CD44
16	leukemia, chronic lymphocytic 2	31.7	BCL2 ATM
17	leukemia, acute myeloid	31.7	MTOR MDM2 MALAT1 EZH2 CDKN2A CD44
18	mature b-cell neoplasm	31.7	IRF4 CDKN2A CCND1 BCL6 BCL2
19	peripheral nervous system disease	31.6	MTOR MDM2 EZH2 CDKN2A CD44 CCND1
20	lymphatic system disease	31.6	MIR16-1 IRF4 BCL6 BCL2
21	lymphoplasmacytic lymphoma	31.5	IRF4 CCND1 BCL6 BCL2
22	retinoblastoma	31.5	MDM2 MALAT1 CDKN2C CDKN2A CCNG1 CCND2
23	composite lymphoma	31.5	BCL6 BCL2
24	richter's syndrome	31.5	BCL6 BCL2 ATM
25	adenocarcinoma	31.4	MDM2 MALAT1 CDKN2A CCND1 C11orf65 BCL2
26	t-cell acute lymphoblastic leukemia	31.4	IRF4 GAS5 CCND2 BCL2 ATM
27	leukemia, acute lymphoblastic	31.4	IRF4 IGH CDKN2C CDKN2A CCND2 BCL6
28	lung cancer susceptibility 3	31.3	MALAT1 GAS5 CDKN2A CCND1 BCL2
29	gastrointestinal lymphoma	31.3	CCND1 BCL6 BCL2
30	breast cancer	31.3	MTOR MDM2 MALAT1 GAS5 EZH2 CDKN2A
31	myelodysplastic syndrome	31.3	EZH2 CDKN2C CDKN2A BMI1 BCL2
32	colon lymphoma	31.2	CCND1 BCL6 BCL2
33	nodal marginal zone lymphoma	31.2	IRF4 BCL6 BCL2
34	reticulosarcoma	31.2	IGH BCL6 BCL2
35	squamous cell carcinoma	31.2	MTOR MDM2 MALAT1 CDKN2A CD44 CCND1
36	testicular lymphoma	31.1	IRF4 BCL6 BCL2
37	prostate cancer	31.1	MTOR MIR16-1 MDM2 MALAT1 GAS5 EZH2
38	acute promyelocytic leukemia	31.1	MIR16-1 EZH2 CCND1 BCL6 BCL2
39	colonic benign neoplasm	31.1	CDKN2A CD44 CCND1 C11orf65 BCL2 ATM
40	plasmacytoma	31.0	MTOR IRF4 IGH GAS5 CDKN2A CCND1
41	renal cell carcinoma, nonpapillary	31.0	MTOR MALAT1 GAS5 EZH2 CDKN2A CD44
42	adenoma	31.0	CDKN2A CD44 CCND1 BCL2
43	gastrointestinal stromal tumor	31.0	MTOR MDM2 CDKN2A CCND1 BCL2
44	breast lymphoma	31.0	IRF4 BCL6 BCL2
45	meningioma, familial	31.0	MDM2 CDKN2C CDKN2A CCND1 BCL2
46	gastric lymphoma	31.0	IRF4 BCL6 BCL2
47	pancreatic cancer	30.8	MTOR MIR16-1 MDM2 MALAT1 GAS5 EZH2
48	nervous system disease	30.8	MTOR MIR16-1 MDM2 EZH2 CDKN2A CD44
49	neuroblastoma	30.8	MTOR MDM2 MALAT1 GAS5 EZH2 CDKN2A
50	nasopharyngeal carcinoma	30.8	MDM2 MALAT1 GAS5 EZH2 CDKN2A CD44

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:

Sources

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

⁵⁸ ³⁰ (show all 9)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	lymphadenopathy ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002716
2	b-cell lymphoma ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012191
3	splenomegaly ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001744
4	fatigue ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012378
5	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
6	anorexia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002039
7	weight loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001824
8	abnormality of bone marrow cell morphology ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0005561
9	abnormality of the gastrointestinal tract ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011024

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	ATM BCL6 CCND1 CCNG1 CD44 MDM2

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

⁴⁵ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.41	ATM BCL2 BCL6 BMI1 CCND1 CCND2
2	nervous system	MP:0003631	10.31	ATM BCL2 BMI1 CCND1 CCND2 CD44
3	growth/size/body region	MP:0005378	10.31	ATM BCL2 BCL6 BMI1 CCND1 CCND2
4	cellular	MP:0005384	10.31	ATM BCL2 BCL6 BMI1 CCND1 CCNG1
5	neoplasm	MP:0002006	10.29	ATM BCL2 BMI1 CCND1 CCNG1 CD44
6	endocrine/exocrine gland	MP:0005379	10.29	ATM BCL2 BCL6 BMI1 CCND1 CCND2
7	immune system	MP:0005387	10.21	ATM BCL2 BCL6 BMI1 CCND1 CCND2
8	cardiovascular system	MP:0005385	10.18	ATM BCL2 BCL6 BMI1 CCND1 CCND2
9	adipose tissue	MP:0005375	10.07	ATM BCL2 BCL6 BMI1 CCND2 IRF4
10	digestive/alimentary	MP:0005381	10.06	BCL2 BMI1 CCND1 CCNG1 CD44 CDKN2A
11	reproductive system	MP:0005389	10	ATM BCL2 BCL6 BMI1 CCND1 CCND2
12	hematopoietic system	MP:0005397	9.97	ATM BCL2 BCL6 BMI1 CCND1 CCND2
13	respiratory system	MP:0005388	9.92	BCL6 BMI1 CCND1 CD44 CDKN2A CDKN2C
14	mortality/aging	MP:0010768	9.8	ATM BCL2 BCL6 BMI1 CCND1 CCND2
15	integument	MP:0010771	9.28	ATM BCL2 BCL6 CCND1 CD44 CDKN2A

Sources

Drugs & Therapeutics for Mantle Cell Lymphoma

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Cytarabine

Approved, Experimental, Investigational

Phase 3

147-94-4, 65-46-3

596 6253 6175

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Melphalan

Approved

Phase 3

148-82-3

4053 460612

Carmustine

Approved, Investigational

Phase 3

154-93-8

2578

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Etoposide

Approved

Phase 3

33419-42-0

36462

Aldesleukin

Approved

Phase 3

110942-02-4

Cladribine

Approved, Investigational

Phase 3

4291-63-8

20279

Chlorambucil

Approved

Phase 3

305-03-3

2708

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Epirubicin

Approved

Phase 3

56420-45-2

41867

Vindesine

Approved, Investigational

Phase 3

59917-39-4, 53643-48-4

40839

Rituximab

Approved

Phase 3

174722-31-7

Antineoplastic Agents, Alkylating

Phase 3

Antimetabolites

Phase 3

Antibiotics, Antitubercular

Phase 3

Immunosuppressive Agents

Phase 3

Anti-Bacterial Agents

Phase 3

Alkylating Agents

Phase 3

Gastrointestinal Agents

Phase 3

glucocorticoids

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Antiemetics

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Anti-Inflammatory Agents

Phase 3

Mitogens

Phase 3

interferons

Phase 3

Interferon-alpha

Phase 3

Interferon alpha-2

Phase 3

Anti-Infective Agents

Phase 3

Antiviral Agents

Phase 3

Etoposide phosphate

Phase 3

16760419

Interleukin-2

Phase 3

Anti-HIV Agents

Phase 3

Anti-Retroviral Agents

Phase 3

Analgesics, Non-Narcotic

Phase 3

Analgesics

Phase 3

Protein Kinase Inhibitors

Phase 3

Liposomal doxorubicin

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Antirheumatic Agents

Phase 3

Immunologic Factors

Phase 3

Interventional clinical trials:

(show top 50) (show all 664)

#	Name	Status	NCT ID	Phase	Drugs
1	EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial	Unknown status	NCT02858804	Phase 4	Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
2	A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA	Completed	NCT01180049	Phase 4	temsirolimus
3	A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma	Recruiting	NCT04930536	Phase 4	Acalabrutinib capsule
4	A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion	Active, not recruiting	NCT03190330	Phase 4	Ibrutinib 420 mg;Ibrutinib 560 mg
5	Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma	Unknown status	NCT01449344	Phase 3	Rituximab;High dose Ara-C;Dexamethasone;Bortezomib
6	Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation	Unknown status	NCT00209209	Phase 3	Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Fludarabine;Interferon-alpha;pegylated formula Interferon-alpha 2b
7	Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial	Unknown status	NCT01933711	Phase 3	rituximab
8	A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma	Unknown status	NCT02354313	Phase 3	Lenalidomide
9	Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Unknown status	NCT02991638	Phase 3	Ibrutinib
10	Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation	Unknown status	NCT00209222	Phase 3	Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
11	Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination	Unknown status	NCT00016887	Phase 3	carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
12	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
13	A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma	Completed	NCT00269113	Phase 3	rituximab [MabThera/Rituxan];Standard chemotherapy
14	A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)	Completed	NCT01073163	Phase 3	Bendamustine;Rituximab
15	Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma	Completed	NCT00641095	Phase 2, Phase 3	Cyclophosphamide;Fludarabine
16	A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4	Completed	NCT00003280	Phase 3
17	An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)	Completed	NCT00117598	Phase 3	Temsirolimus (CCI-779);Investigator's choice
18	A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant	Completed	NCT00722137	Phase 3	Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
19	An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)	Completed	NCT00877006	Phase 3	bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
20	A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy	Completed	NCT01646021	Phase 3	Ibrutinib;Temsirolimus
21	Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas	Completed	NCT01456351	Phase 3	Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
22	A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
23	Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL	Completed	NCT00921414	Phase 3	Rituximab
24	A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
25	A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of (dUCB) Versus HLA-Haplo Related Bone Marrow for Patients With Hematologic Malignancies.(BMT CTN #1101)	Completed	NCT01597778	Phase 3
26	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma	Completed	NCT00002649	Phase 3	cyclophosphamide;etoposide
27	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma	Recruiting	NCT02972840	Phase 3	Acalabrutinib;Bendamustine;Rituximab;Placebo
28	A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)	Recruiting	NCT04662255	Phase 3	Pirtobrutinib;Ibrutinib;Acalabrutinib;Zanubrutinib
29	A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation	Recruiting	NCT04002297	Phase 3	zanubrutinib;bendamustine;rituximab
30	A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma	Recruiting	NCT05051891	Phase 3	Orelabrutinib and R-CHOP;R-CHOP
31	Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial	Recruiting	NCT02858258	Phase 3	R-CHOP/R-DHAP;Ibrutinib (Induction);ASCT conditioning;Ibrutinib (Maintenance)
32	A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission	Recruiting	NCT03267433	Phase 3
33	A Multi-center, Prospective Clinical Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma	Recruiting	NCT05164770	Phase 3	Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX;R-CHOP; R-DA-EPOCH; R-HD MTX
34	Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial	Recruiting	NCT05020392	Phase 3	BTK inhibitor+ Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells;Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
35	A Multi-center and Prospective Clinical Study of Orelabrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma	Recruiting	NCT05097443	Phase 3	Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
36	A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma	Active, not recruiting	NCT01996865	Phase 3	Lenalidomide;Rituximab
37	Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma	Active, not recruiting	NCT01865110	Phase 3	R-CHOP;R-CHOP / R-HAD;Rituximab;Lenalidomide
38	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma	Active, not recruiting	NCT01776840	Phase 3	Bendamustine;Rituximab;Ibrutinib;Placebo
39	Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma	Active, not recruiting	NCT03112174	Phase 3	Ibrutinib;Venetoclax;Placebo Oral tablet to match Venetoclax
40	Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas	Active, not recruiting	NCT00877214	Phase 3	Rituximab;Rituximab / observation
41	A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study	Enrolling by invitation	NCT01804686	Phase 3	Ibrutinib
42	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	Not yet recruiting	NCT05431179	Phase 3	Zilovertamab;Ibrutinib;Placebo
43	A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician's Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants With Relapsed or Refractory Mantle Cell Lymphoma	Not yet recruiting	NCT05564052	Phase 2, Phase 3	Ibrutinib;Lenalidomide;Rituximab;Bortezomib
44	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma	Terminated	NCT01021423	Phase 3	Lenalidomide
45	UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies	Terminated	NCT00714259	Phase 2, Phase 3	Fludarabine
46	A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma	Terminated	NCT02793583	Phase 2, Phase 3	Umbralisib
47	A Phase 3, Randomized, Double-Blind Study Comparing Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab (BR), With Placebo and BR for the Treatment of Newly Diagnosed Mantle Cell Lymphoma	Withdrawn	NCT04849715	Phase 3	parsaclisib;rituximab;bendamustine;Placebo
48	A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)	Withdrawn	NCT02735876	Phase 3	acalabrutinib;ibrutinib;rituximab
49	A Two-Arm, Single-Center, Open-Label Pilot Study of IL-2 Programmed or IL-7/IL-15 Programmed Anti-CD19:TCRz:CD28 T-cells in Patient With CD19-Positive Lymphoma That is Resistant or Refractory to Chemotherapy	Unknown status	NCT02652910	Phase 1, Phase 2	CD19.CAR-T cells
50	A Phase I/II Study of Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 Chimeric Antigen Receptor T-Cells in Patients With Refractory CD19+ B-lineage Leukemia/Lymphoma	Unknown status	NCT02685670	Phase 1, Phase 2	Fludarabine;Cyclophosphamide

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Ibrutinib

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Mantle Cell Lymphoma:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
	Peripheral blood stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Mantle Cell Lymphoma:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743

Cochrane evidence based reviews: lymphoma, mantle-cell

Sources

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

#	Genetic test	Affiliating Genes
1	Mantle Cell Lymphoma ²⁸

Sources

Anatomical Context for Mantle Cell Lymphoma

Organs/tissues related to Mantle Cell Lymphoma:

MalaCards : B Cells, Lymph Node, T Cells, Bone Marrow, Bone, Nk Cells, Myeloid

Sources

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 5615)

#	Title	Authors	PMID	Year
1	Mantle cell lymphoma is characterized by inactivation of the ATM gene. ⁶² ⁵	Schaffner C...Lichter P	10706620	2000
2	Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. ⁶² ⁴⁶	Chen RW...Robinson WA	18483394	2008
3	Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. ⁵³ ⁶²	Metcalf RA...Natkunam Y	20062012	2010
4	Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. ⁵³ ⁶²	Hartmann E...Campo E	18606985	2008
5	Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. ⁵³ ⁶²	Hartmann E...Rosenwald A	17488676	2007
6	[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]. ⁵³ ⁶²	Mounier N...Spano JP	17145584	2006
7	Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. ⁵³ ⁶²	Filippi AR...Ricardi U	16956411	2006
8	Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. ⁵³ ⁶²	Camps J...Campo E	16448697	2006
9	Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. ⁵³ ⁶²	van Kemenade FJ...Meijer CJ	11389032	2001
10	Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. ⁵³ ⁶²	Aguilera NS...Taubenberger JK	9846986	1998
11	Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. ⁵³ ⁶²	Williams ME...Swerdlow SH	9209645	1997
12	Chronic lymphoproliferative disorders. ⁵³ ⁶²	Montserrat E	9090492	1997
13	Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. ⁵³ ⁶²	Chesi M...Kuehl WM	8695815	1996
14	Mantle-cell lymphoma: classification and therapeutic implications. ⁵³ ⁶²	Fisher RI	9010577	1996
15	Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. ⁵³ ⁶²	Delmer A...Zittoun R	7772515	1995
16	Histogenesis and pathogenesis of follicular small cleaved cell lymphoma (FSCCL), diffuse small cleaved cell lymphoma (DSCCL) and intermediate lymphocytic lymphoma/lymphocytic lymphoma of intermediate differentiation (ILL/IDL). ⁵³ ⁶²	Abe M...Wakasa H	7642169	1994
17	The presence of bcl-1 and bcl-2 gene rearrangements in diffuse small cleaved-cell lymphoma. A disease with diverse molecular and immunophenotypic findings. ⁵³ ⁶²	Leith CP...Grogan TM	7981893	1994
18	Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. ⁵³ ⁶²	Rimokh R...Vuillaume M	8204893	1994
19	PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. ⁵³ ⁶²	Oka K...Shirakawa S	7918073	1994
20	Identification of genetic lesions associated with diffuse large-cell lymphoma. ⁵³ ⁶²	Dalla-Favera R...Chaganti RS	8172819	1994
21	bcl-2 gene expression in hematopoietic cell differentiation. ⁵³ ⁶²	Mariano MT...Narni F	1638028	1992
22	Histogenesis of diffuse small cleaved cell lymphoma. An immunohistochemical and molecular genetic (bcl-2 gene) study with comparison to follicular small cleaved cell lymphoma and mantle zone lymphoma. ⁵³ ⁶²	Abe M...Wakasa H	1643614	1992
23	Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. ⁶²	Petrackova A...Kriegova E	36029002	2022
24	Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. ⁶²	Sharma S...Tomkinson H	35466438	2022
25	Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease. ⁶²	Tarockoff M...Sandoval-Sus J	35639332	2022
26	Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. ⁶²	Janssens A...Andre M	36227519	2022
27	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. ⁶²	Munoz JL...Wang M	35596920	2022
28	IBCL-429 Prevalence of B-Cell Chronic Lymphoproliferative Disorders at a Large Tertiary Care Center in India. ⁶²	Gogia A...Mallick S	36164116	2022
29	Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway. ⁶²	Chen S...Yang C	36252483	2022
30	Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape. ⁶²	Mangolini M...Ringshausen I	36266281	2022
31	Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation. ⁶²	Thus YJ...Spaargaren M	36226498	2022
32	IBCL-349 Veterans With Agent Orange Exposure Have a Shorter Latency From Exposure to Diagnosis of Indolent B-Cell Lymphoid Malignancies Compared to Unexposed Veterans. ⁶²	Ma H...Cozen W	36164109	2022
33	CXCR4-targeted theranostics in oncology. ⁶²	Buck AK...Werner RA	35674738	2022
34	MCL-319 LP-284 - A Highly Potent Small Molecule Targeting Mantle Cell Lymphoma. ⁶²	Zhou J...Dave S	36164123	2022
35	IBCL-081 MAGNIFY Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis. ⁶²	Lansigan F...Sharman JP	36164099	2022
36	Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study. ⁶²	Wang Y...Liu P	35859066	2022
37	Circulating Tumor DNA in Lymphoma. ⁶²	Kambhampati S...Zain J	36214943	2022
38	CT-321 Uncommon Viral Infections in Patients Treated With CAR-T Cell Therapy: Concurrent Adenovirus and BK Virus Infection in a Mantle Cell Lymphoma Patient Within 30 Days After Receiving Brexucabtagene Autoleucel. ⁶²	Tregubenko P...Abdelhakim H	36164215	2022
39	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. ⁶²	Freeman CL...Lenz G	35963941	2022
40	[scRNA-sequencing uncovers metabolism and CD52 as new targets in ibrutinib-surviving mantle cell lymphoma cells]. ⁶²	Fuhr V...Rauert-Wunderlich H	36222922	2022
41	[18F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma. ⁶²	Vergote VKJ...Deroose CM	36223113	2022
42	Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease. ⁶²	O'Reilly MA...BSH Guidelines Committee Haemato-oncology Task Force	35894253	2022
43	Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma. ⁶²	Kliebhan J...Driessen C	36225622	2022
44	'Primary CNS Blastoid Variant of Mantle Cell Lymphoma: A Unique Case'. ⁶²	Sarkar A...Dey D	36258737	2022
45	Prognostic value and computer image analysis of p53 in mantle cell lymphoma. ⁶²	Zhang YH...Liu WP	35918462	2022
46	Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. ⁶²	Rai S...Tajimi M	35984628	2022
47	Mantle cell lymphoma in human immunodeficiency virus-infected patients. ⁶²	Bertinchamp R...Gerard L	36223890	2022
48	Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy? ⁶²	Beitinjaneh A...Wang M	36227407	2022
49	EXABS-204-MCL The Role of Targeted Therapies in Frontline Treatment of Mantle Cell Lymphoma. ⁶²	Takiar R...Phillips TJ	36164250	2022
50	EXABS-206-MCL Emerging Treatment Options for Mantle Cell Lymphoma. ⁶²	Ruan J	36164252	2022

Sources

Genes for Mantle Cell Lymphoma

Genes related to Mantle Cell Lymphoma (5 elite genes):

(show top 50) (show all 110)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ATM	ATM Serine/Threonine Kinase	Protein Coding	790.67	Pathogenic ⁵ Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Functions (show sections)	10706620 16956411
2	CCND1	Cyclin D1	Protein Coding	403.25	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Functions (show sections)	7981893 7642169 20062012 (more) 9846986 8204893 7772515 9010577 9209645 7918073 8695815 16448697 17145584 8172819 8172823 18606985
2	CCND1::MIR16-1 ⁴⁶	MIR16-1 Macro RNA (hsa-miR-16-1) targets CCND1
3	C11orf65	Chromosome 11 Open Reading Frame 65	Protein Coding	400	Pathogenic ⁵	10706620
4	MIR16-1	MicroRNA 16-1	RNA Gene	361.03	Causal ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	18483394
5	IGH	Immunoglobulin Heavy Locus	Protein Coding	350	Causative somatic mutation ⁵⁸	12601901 11245476
6	ROR1-AS1	ROR1 Antisense RNA 1	RNA Gene	154.81	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29113297
7	GAS5	Growth Arrest Specific 5	RNA Gene	153.85	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24703244
8	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	152.84	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27998273
9	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	21.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11389032
10	BMI1	BMI1 Proto-Oncogene, Polycomb Ring Finger	Protein Coding	21.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11389032 16528373
11	BCL2	BCL2 Apoptosis Regulator	Protein Coding	20.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7981893 1643614 7642169 (more) 1638028 9090492 8172819
12	MDM2	MDM2 Proto-Oncogene	Protein Coding	18.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17488676
13	CCNG1	Cyclin G1	Protein Coding	18.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9209645
14	CCND2	Cyclin D2	Protein Coding	14.96	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	14.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	14.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	BCL6	BCL6 Transcription Repressor	Protein Coding	13.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9209651
18	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	12.63	DISEASES inferred ¹⁴ GeneCards inferred via : Functions (show sections)
19	CDKN2C	Cyclin Dependent Kinase Inhibitor 2C	Protein Coding	12.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	IRF4	Interferon Regulatory Factor 4	Protein Coding	9.62	DISEASES inferred ¹⁴ ¹⁴
21	MIR155	MicroRNA 155	RNA Gene	9.36	DISEASES inferred ¹⁴ ¹⁴
22	H2AC18	H2A Clustered Histone 18	Protein Coding	9.33	DISEASES inferred ¹⁴ ¹⁴
23	MIR17	MicroRNA 17	RNA Gene	8.77	DISEASES inferred ¹⁴ ¹⁴
24	BTK	Bruton Tyrosine Kinase	Protein Coding	8.71	DISEASES inferred ¹⁴
25	CD5	CD5 Molecule	Protein Coding	8.52	DISEASES inferred ¹⁴
26	IGHV4-38-2	Immunoglobulin Heavy Variable 4-38-2	Protein Coding	8.25	DISEASES inferred ¹⁴
27	SOX11	SRY-Box Transcription Factor 11	Protein Coding	8.18	DISEASES inferred ¹⁴
28	CD19	CD19 Molecule	Protein Coding	7.94	DISEASES inferred ¹⁴
29	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	7.93	DISEASES inferred ¹⁴ ¹⁴
30	KDM4C	Lysine Demethylase 4C	Protein Coding	7.6	DISEASES inferred ¹⁴ ¹⁴
31	MME	Membrane Metalloendopeptidase	Protein Coding	7.6	DISEASES inferred ¹⁴
32	TP53	Tumor Protein P53	Protein Coding	7.41	DISEASES inferred ¹⁴
33	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	7.37	DISEASES inferred ¹⁴
34	MIR26A1	MicroRNA 26a-1	RNA Gene	7.34	DISEASES inferred ¹⁴ ¹⁴
35	CD22	CD22 Molecule	Protein Coding	7.32	DISEASES inferred ¹⁴
36	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.29	DISEASES inferred ¹⁴ ¹⁴
37	CD79B	CD79b Molecule	Protein Coding	7.25	DISEASES inferred ¹⁴
38	MCL1	MCL1 Apoptosis Regulator, BCL2 Family Member	Protein Coding	7.24	DISEASES inferred ¹⁴
39	MIR9-1	MicroRNA 9-1	RNA Gene	7.18	DISEASES inferred ¹⁴ ¹⁴
40	CD79A	CD79a Molecule	Protein Coding	7.13	DISEASES inferred ¹⁴
41	RAD1	RAD1 Checkpoint DNA Exonuclease	Protein Coding	6.99	DISEASES inferred ¹⁴
42	SPN	Sialophorin	Protein Coding	6.98	DISEASES inferred ¹⁴
43	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.96	DISEASES inferred ¹⁴
44	PMAIP1	Phorbol-12-Myristate-13-Acetate-Induced Protein 1	Protein Coding	6.95	DISEASES inferred ¹⁴
45	PAX5	Paired Box 5	Protein Coding	6.93	DISEASES inferred ¹⁴
46	MIR615	MicroRNA 615	RNA Gene	6.91	DISEASES inferred ¹⁴ ¹⁴
47	BCL2L1	BCL2 Like 1	Protein Coding	6.85	DISEASES inferred ¹⁴
48	BCL2L11	BCL2 Like 11	Protein Coding	6.76	DISEASES inferred ¹⁴
49	SYK	Spleen Associated Tyrosine Kinase	Protein Coding	6.73	DISEASES inferred ¹⁴
50	CD38	CD38 Molecule	Protein Coding	6.72	DISEASES inferred ¹⁴

Sources

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

IMPROVED

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ATM	NM_000051.4(ATM):c.4081C>T (p.Gln1361Ter)	SNV	Pathogenic	3041	rs121434222	GRCh37: 11:108158414-108158414 GRCh38: 11:108287687-108287687
2	ATM, C11orf65	NM_000051.4(ATM):c.7268A>G (p.Glu2423Gly)	SNV	Pathogenic	3039	rs121434221	GRCh37: 11:108199926-108199926 GRCh38: 11:108329199-108329199
3	ATM, C11orf65	NM_000051.4(ATM):c.7251_7253dup (p.Lys2418_Arg2419insLys)	DUP	Pathogenic	3040	rs796051857	GRCh37: 11:108199908-108199909 GRCh38: 11:108329181-108329182

Copy number variations for Mantle Cell Lymphoma from CNVD:

⁶ (show all 39)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	44978	10	6600000	12200000	Loss		Mantle cell lymphoma
2	49103	11	102900000	110400000	Loss	ACAT1	Mantle cell lymphoma
3	49104	11	102900000	110400000	Loss	ATM	Mantle cell lymphoma
4	49105	11	102900000	110400000	Loss	CUL5	Mantle cell lymphoma
5	49106	11	102900000	110400000	Loss	FDX1	Mantle cell lymphoma
6	49107	11	102900000	110400000	Loss	NPAT	Mantle cell lymphoma
7	49108	11	102900000	110400000	Loss	RAB39A	Mantle cell lymphoma
8	49703	11	110400000	112500000	Loss		Mantle cell lymphoma
9	49990	11	112500000	114500000	Loss	TMPRSS5	Mantle cell lymphoma
10	49991	11	112500000	114500000	Loss	USP28	Mantle cell lymphoma
11	49992	11	112500000	114500000	Loss	ZW10	Mantle cell lymphoma
12	54401	11	43500000	48800000	Loss	TP53I11	Mantle cell lymphoma
13	60881	11	92800000	97200000	Loss	MAML2	Mantle cell lymphoma
14	61262	11	97200000	102100000	Loss	BIRC2	Mantle cell lymphoma
15	61263	11	97200000	102100000	Loss	BIRC3	Mantle cell lymphoma
16	74176	13	101700000	104800000	Loss	BIVM	Mantle cell lymphoma
17	74177	13	101700000	104800000	Loss	ERCC5	Mantle cell lymphoma
18	74178	13	101700000	104800000	Loss	POGLUT2	Mantle cell lymphoma
19	74694	13	110300000	115169878	Loss	TMCO3	Mantle cell lymphoma
20	74695	13	110300000	115169878	Loss	DCUN1D2	Mantle cell lymphoma
21	74696	13	110300000	115169878	Loss	CUL4A	Mantle cell lymphoma
22	74697	13	110300000	115169878	Loss	GRTP1	Mantle cell lymphoma
23	74698	3	117011831	117647068	Loss	LAMP3	Mantle cell lymphoma
24	74699	13	110300000	115169878	Loss	TFDP1	Mantle cell lymphoma
25	77990	13	48877883	49056026	Deletion	RB1	Mantle cell lymphoma
26	79883	13	79000000	95000000	Copy number	MIR17HG	Mantle cell lymphoma
27	80925	13	99300000	101700000	Loss	PCCA	Mantle cell lymphoma
28	118115	17	7571720	7590868	Mutation	TP53	Mantle cell lymphoma
29	141432	2	210288771	210598834	Deletion	MAP2	Mantle cell lymphoma
30	143512	2	237300000	243199373	Loss		Mantle cell lymphoma
31	170852	3	160700000	167600000	Loss	SLITRK3	Mantle cell lymphoma
32	245172	9	102600000	108200000	Loss	INVS	Mantle cell lymphoma
33	248837	9	137400000	141213431	Loss	TRAF2	Mantle cell lymphoma
34	250734	9	21967751	21994490	Deletion	CDKN2A	Mantle cell lymphoma
35	252714	9	36300000	38400000	Loss	MELK	Mantle cell lymphoma
36	254747	9	68700000	72200000	Loss	TJP2	Mantle cell lymphoma
37	256309	9	91800000	93900000	Loss	DIRAS2	Mantle cell lymphoma
38	256992	9	99300000	102600000	Loss	GABBR2	Mantle cell lymphoma
39	256993	9	99300000	102600000	Loss	TBC1D2	Mantle cell lymphoma

Sources

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Sources

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)

#	Super pathways	Score	Top Affiliating Genes
1	Cellular responses to stimuli ⁶⁶ Show member pathways Cellular responses to stress ⁶⁶	13.45	MTOR MDM2 EZH2 CDKN2C CDKN2A BMI1
2	Prolactin Signaling ⁶⁴ Show member pathways "EGFR Inhibitor Pathway, Pharmacodynamics" ⁶⁰ Development Prolactin receptor signaling ²² EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.44	ATM BCL2 CCND1 CCND2 CDKN2A CDKN2C
3	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	12.92	MTOR MDM2 CDKN2A CCNG1 BCL6 ATM
4	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.91	MTOR MDM2 CCND2 CCND1 BCL2
5	ncRNAs involved in Wnt signaling in hepatocellular carcinoma ⁷⁴ Show member pathways lncRNA in canonical Wnt signaling and colorectal cancer ⁷⁴ Wnt signaling ⁷⁴ Wnt signaling pathway and pluripotency ⁷⁴ Wnt Signaling Pathways ⁶⁵	12.79	MIR16-1 EZH2 CD44 CCND2 CCND1
6	Cellular Senescence ⁶⁶ Show member pathways Oxidative Stress Induced Senescence ⁶⁶ Senescence-Associated Secretory Phenotype (SASP) ⁶⁶	12.68	MDM2 EZH2 CDKN2C CDKN2A BMI1 ATM
7	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.67	MTOR MDM2 CDKN2A CCND1 BCL2
8	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects ⁶⁶ Show member pathways "Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)" ⁶⁶ Aberrant regulation of mitotic cell cycle due to RB1 defects ⁶⁶ Aberrant regulation of mitotic exit in cancer due to RB1 defects ⁶⁶ Cell cycle Cell cycle (generic schema) ²² Cell cycle Regulation of G1/S transition (part 2) ²² Cyclin D associated events in G1 ⁶⁶ Defective translocation of RB1 mutants to the nucleus ⁶⁶ Diseases of mitotic cell cycle ⁶⁶ Drug-mediated inhibition of CDK4/CDK6 activity ⁶⁶ G1 Phase ⁶⁶ G2 Phase ⁶⁶ Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes ⁶⁶ PTK6 Regulates Cell Cycle ⁶⁶	12.47	CDKN2C CDKN2A CCND2 CCND1
9	Mitotic G1 phase and G1/S transition ⁶⁶ Show member pathways G1/S Transition ⁶⁶	12.45	CDKN2C CDKN2A CCND2 CCND1
10	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.43	ATM CCND1 MDM2 MTOR
11	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.41	MTOR MDM2 BCL2 ATM
12	DNA Damage ³	12.41	MDM2 CDKN2C CDKN2A CCND2 CCND1 ATM
13	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.23	CCND1 CCND2 IGH MDM2 MTOR
14	Vitamin D receptor pathway ⁷⁴	12.21	IRF4 CDKN2C CDKN2A CCND1 BCL6
15	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.17	MDM2 CCND1 BCL2 ATM
16	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.17	MTOR MDM2 CCND2 CCND1 BCL2
17	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.11	MDM2 CDKN2C CDKN2A CCND2 CCND1 ATM
18	Integrated breast cancer pathway ⁷⁴	12.1	MTOR MDM2 CCND1 BCL2 ATM
19	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ G1-S Phase Transition ⁶⁴	12.04	CDKN2C CDKN2A CCND2 CCND1 ATM
20	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.02	ATM CCND1 CCND2 CCNG1 MDM2
21	Direct p53 effectors ⁶¹	12.01	MDM2 CCNG1 BCL6 BCL2
22	Gastrin signaling pathway ⁷⁴	11.94	CDKN2A CD44 CCND1
23	Malignant pleural mesothelioma ⁷⁴	11.93	MTOR MDM2 EZH2 CDKN2A CD44 CCND2
24	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.92	IRF4 CCND1 BCL6 BCL2
25	Notch Signaling Pathways ⁶⁵	11.88	MTOR CCND1 BCL6 BCL2
26	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.87	MDM2 CDKN2A ATM
27	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.84	MTOR CD44 CCND1
28	DNA IR-damage and cellular response via ATR ⁷⁴	11.77	MDM2 BCL6 ATM
29	C-MYB transcription factor network ⁶¹	11.77	CDKN2A CCND1 BCL2
30	Neural Stem Cells and Lineage-specific Markers ⁶⁵	11.76	EZH2 CD44 BMI1
31	Head and neck squamous cell carcinoma ⁷⁴	11.72	CCND1 CDKN2A MTOR
32	MECP2 and associated Rett syndrome ⁷⁴	11.72	BCL6 EZH2 MTOR
33	Regulation of nuclear beta catenin signaling and target gene transcription ⁶¹	11.71	CDKN2A CCND2 CCND1
34	Regulation of Telomerase ⁶¹	11.68	MTOR CCND1 ATM
35	Transcription_P53 signaling pathway ²²	11.68	MDM2 CDKN2A BCL2 ATM
36	miRNAs involved in DNA damage response ⁷⁴	11.67	MIR16-1 CCND1 ATM
37	E2F transcription factor network ⁶¹	11.66	CDKN2C CDKN2A ATM
38	Senescence and autophagy in cancer ⁷⁴	11.65	MTOR MDM2 CDKN2A CD44 BMI1 BCL2
39	Prader-Willi and Angelman syndrome ⁷⁴	11.62	CDKN2C CDKN2A CCND2 CCND1
40	IL4-mediated signaling events ⁶¹	11.61	MTOR IRF4 BCL6
41	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.59	ATM CCNG1 CDKN2A MDM2 MTOR
42	p53 pathway ⁶¹	11.51	MDM2 CDKN2A CCNG1 ATM
43	Validated transcriptional targets of deltaNp63 isoforms ⁶¹	11.48	MDM2 CDKN2A ATM
44	DNA damage response (only ATM dependent) ⁷⁴	11.44	MDM2 CCND2 CCND1 BCL6 BCL2 ATM
45	Hedgehog signaling pathway ⁷⁴	11.42	CCND2 CCND1 BCL2
46	Bladder cancer ⁷⁴	11.4	MDM2 CDKN2A CCND1
47	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.38	MDM2 CCND2 CCND1 ATM
48	Integrated cancer pathway ⁷⁴	11.37	ATM BCL2 MDM2
49	Oncogene Induced Senescence ⁶⁶	11.29	MDM2 CDKN2C CDKN2A
50	GADD45 Pathway ⁶⁴	11.21	CCNG1 CCND2 CCND1 ATM

Sources

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cyclin-dependent protein kinase holoenzyme complex	GO:0000307	9.1	CCNG1 CCND2 CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of apoptotic process	GO:0043065	10.13	MIR16-1 CDKN2A BCL6 BCL2 ATM
2	cell cycle	GO:0007049	10.1	ATM CCND1 CCND2 CCNG1 CDKN2A CDKN2C
3	negative regulation of cell growth	GO:0030308	10.03	CDKN2C CDKN2A BCL6 BCL2
4	negative regulation of apoptotic process	GO:0043066	10.03	MTOR MDM2 CD44 CCNG1 CCND2 BCL6
5	cellular response to hypoxia	GO:0071456	10	MTOR MDM2 MALAT1 BCL2
6	positive regulation of B cell proliferation	GO:0030890	9.95	BMI1 BCL6 BCL2
7	regulation of G1/S transition of mitotic cell cycle	GO:2000045	9.93	CDKN2C CDKN2A CCND1
8	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.91	MIR16-1 EZH2 BCL2
9	mitotic cell cycle phase transition	GO:0044772	9.8	CCNG1 CCND2 CCND1
10	G1/S transition of mitotic cell cycle	GO:0000082	9.76	BCL2 CCND1 CCND2 EZH2
11	regulation of cell cycle	GO:0051726	9.65	MDM2 CDKN2A CCNG1 CCND2 CCND1 BCL2
12	positive regulation of response to stimulus	GO:0048584	9.55	MTOR ATM
13	response to stress	GO:0006950	9.4	ATM MTOR
14	regulation of nucleobase-containing compound metabolic process	GO:0019219	9.37	MTOR ATM
15	regulation of cyclin-dependent protein serine/threonine kinase activity	GO:0000079	9.32	CDKN2C CDKN2A CCNG1 CCND2 CCND1